Private healthcare provider Parkway Pantai has acquired 55% stake of Angsana holding Pte ltd which is specialist in developing premium genomic essays. Angsana holding is also a provider of Next generation sequencing which can retrieve more comprehensive genetic information from tumour tissue. Through NGs doctor can able to determine which drugs are more suitable and effective for the patients.
Dr Tan See Leng, Group Chief Executive Officer and Managing Director of Parkway Pantai said “With Angsana Molecular and Diagnostics, we now have the molecular capabilities to customise medical treatment for each individual patient. Precision medicine enables doctors and patients to make better informed decisions on how to manage diseases more efficiently and safely”.
Parway Pantai has bought 55% stake for $9.3 million. Angsana runs two college of American Pathologist (CAP). The laboratories of these colleges are in Singapore and Hong Kong.
Dr Chris Tan, Chief Executive Officer and Founder of Angsana Molecular & Diagnostic said “We are committed to deliver high-performance and affordable molecular diagnostic services to tailor treatment to the needs and characteristics of individual patients. We are excited to work with Parkway Pantai’s vast network of healthcare facilities to meet the health demand of the Asian population.”
